Traders Buy Pfizer, Inc. (PFE) on Weakness

Traders purchased shares of Pfizer, Inc. (NYSE:PFE) on weakness during trading hours on Monday. $120.51 million flowed into the stock on the tick-up and $69.75 million flowed out of the stock on the tick-down, for a money net flow of $50.76 million into the stock. Of all stocks tracked, Pfizer had the 6th highest net in-flow for the day. Pfizer traded down ($0.36) for the day and closed at $35.98

Several analysts have recently issued reports on the company. Deutsche Bank AG set a $38.00 price objective on Pfizer and gave the company a “buy” rating in a research note on Wednesday, October 11th. BMO Capital Markets set a $37.00 price objective on Pfizer and gave the company a “buy” rating in a research note on Tuesday, October 10th. Barclays PLC set a $38.00 price objective on Pfizer and gave the company a “buy” rating in a research note on Wednesday, October 11th. Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Finally, Jefferies Group LLC set a $38.00 price objective on Pfizer and gave the company a “neutral” rating in a research note on Monday. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $38.15.

The stock has a 50-day moving average of $35.25 and a 200 day moving average of $33.76. The stock has a market cap of $215.29 billion, a P/E ratio of 26.48 and a beta of 1.00.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The business had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.64 EPS. On average, equities research analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be paid a $0.32 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.54%. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.

In related news, CEO Ian C. Read sold 197,168 shares of the business’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $6,703,712.00. Following the completion of the sale, the chief executive officer now owns 580,318 shares of the company’s stock, valued at approximately $19,730,812. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $249,900.00. Following the sale, the insider now directly owns 132,124 shares of the company’s stock, valued at approximately $4,492,216. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 464,521 shares of company stock valued at $15,813,961. Insiders own 0.06% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Altfest L J & Co. Inc. grew its position in shares of Pfizer by 67.0% during the 2nd quarter. Altfest L J & Co. Inc. now owns 107,278 shares of the biopharmaceutical company’s stock valued at $3,603,000 after buying an additional 43,024 shares during the last quarter. Sphera Funds Management LTD. bought a new stake in shares of Pfizer during the 1st quarter valued at about $13,342,000. Searle & CO. grew its position in shares of Pfizer by 92.7% during the 1st quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock valued at $2,739,000 after buying an additional 38,500 shares during the last quarter. Insight 2811 Inc. grew its position in shares of Pfizer by 3.7% during the 1st quarter. Insight 2811 Inc. now owns 9,324 shares of the biopharmaceutical company’s stock valued at $319,000 after buying an additional 329 shares during the last quarter. Finally, Washington Trust Bank grew its position in shares of Pfizer by 0.7% during the 2nd quarter. Washington Trust Bank now owns 51,052 shares of the biopharmaceutical company’s stock valued at $1,715,000 after buying an additional 377 shares during the last quarter. 68.98% of the stock is owned by institutional investors a

Several analysts have recently issued reports on the company. Deutsche Bank AG set a $38.00 price objective on Pfizer and gave the company a “buy” rating in a research note on Wednesday, October 11th. BMO Capital Markets set a $37.00 price objective on Pfizer and gave the company a “buy” rating in a research note on Tuesday, October 10th. Barclays PLC set a $38.00 price objective on Pfizer and gave the company a “buy” rating in a research note on Wednesday, October 11th. Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Finally, Jefferies Group LLC set a $38.00 price objective on Pfizer and gave the company a “neutral” rating in a research note on Monday. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $38.15.

The stock has a 50-day moving average of $35.25 and a 200 day moving average of $33.76. The stock has a market cap of $215.29 billion, a P/E ratio of 26.48 and a beta of 1.00.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The business had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.64 EPS. On average, equities research analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be paid a $0.32 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.54%. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.

In related news, CEO Ian C. Read sold 197,168 shares of the business’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $6,703,712.00. Following the completion of the sale, the chief executive officer now owns 580,318 shares of the company’s stock, valued at approximately $19,730,812. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $249,900.00. Following the sale, the insider now directly owns 132,124 shares of the company’s stock, valued at approximately $4,492,216. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 464,521 shares of company stock valued at $15,813,961. Insiders own 0.06% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Altfest L J & Co. Inc. grew its position in shares of Pfizer by 67.0% during the 2nd quarter. Altfest L J & Co. Inc. now owns 107,278 shares of the biopharmaceutical company’s stock valued at $3,603,000 after buying an additional 43,024 shares during the last quarter. Sphera Funds Management LTD. bought a new stake in shares of Pfizer during the 1st quarter valued at about $13,342,000. Searle & CO. grew its position in shares of Pfizer by 92.7% during the 1st quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock valued at $2,739,000 after buying an additional 38,500 shares during the last quarter. Insight 2811 Inc. grew its position in shares of Pfizer by 3.7% during the 1st quarter. Insight 2811 Inc. now owns 9,324 shares of the biopharmaceutical company’s stock valued at $319,000 after buying an additional 329 shares during the last quarter. Finally, Washington Trust Bank grew its position in shares of Pfizer by 0.7% during the 2nd quarter. Washington Trust Bank now owns 51,052 shares of the biopharmaceutical company’s stock valued at $1,715,000 after buying an additional 377 shares during the last quarter. 68.98% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Traders Buy Pfizer, Inc. (PFE) on Weakness” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://ledgergazette.com/2017/10/18/traders-buy-pfizer-inc-pfe-on-weakness.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply